-Men with a documented clinical diagnosis of ED confirmed by a Sexual Health
Inventory-Male (SHI-M) score of 21 or less and who have a sexual partner for the duration
of the study were included.
- Subjects who have previously taken, or it is suspected they have taken, more than 4
doses of sildenafil citrate, or any other phosphodiesterase type 5 (PDE-5) inhibitor,
or apomorphine, at any time prior to the screening visit or patients who have taken
any dose of these compounds in the last two months
- Subjects with resting sitting hypotension (BP
- Subjects with significant cardiovascular disease, including cardiac failure,
myocardial infarction, unstable angina, stroke or transient ischaemic attack (TIA),
symptomatic or clinically significant cardiac arrhythmias in the last 3 months
- Patients on nitrates.